MX2011011119A - Formulaciones liquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil) fenil] piperazina. - Google Patents
Formulaciones liquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil) fenil] piperazina.Info
- Publication number
- MX2011011119A MX2011011119A MX2011011119A MX2011011119A MX2011011119A MX 2011011119 A MX2011011119 A MX 2011011119A MX 2011011119 A MX2011011119 A MX 2011011119A MX 2011011119 A MX2011011119 A MX 2011011119A MX 2011011119 A MX2011011119 A MX 2011011119A
- Authority
- MX
- Mexico
- Prior art keywords
- dimethylphenylsulfanyl
- liquid formulations
- salts
- piperazine
- phenyl
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical class CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Lubricants (AREA)
Abstract
Se proporcionan formulaciones líquidas de sales de adición del ácido láctico de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21454009P | 2009-04-24 | 2009-04-24 | |
| DKPA200900531 | 2009-04-24 | ||
| PCT/DK2010/050084 WO2010121621A1 (en) | 2009-04-24 | 2010-04-16 | Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011011119A true MX2011011119A (es) | 2011-11-04 |
Family
ID=42669509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011011119A MX2011011119A (es) | 2009-04-24 | 2010-04-16 | Formulaciones liquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil) fenil] piperazina. |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US8940746B2 (es) |
| EP (1) | EP2421534B1 (es) |
| JP (1) | JP5722879B2 (es) |
| KR (1) | KR101779214B1 (es) |
| CN (2) | CN104693145A (es) |
| AR (2) | AR076400A1 (es) |
| AU (1) | AU2010238946B2 (es) |
| BR (1) | BRPI1015338C1 (es) |
| CA (1) | CA2759456C (es) |
| CL (1) | CL2011002631A1 (es) |
| CO (1) | CO6450649A2 (es) |
| CR (1) | CR20110554A (es) |
| DK (1) | DK2421534T3 (es) |
| DO (2) | DOP2011000319A (es) |
| EA (1) | EA021122B1 (es) |
| ES (1) | ES2512719T3 (es) |
| GE (1) | GEP20135938B (es) |
| HK (1) | HK1206732A1 (es) |
| HR (1) | HRP20140880T1 (es) |
| IL (1) | IL215362A0 (es) |
| MA (1) | MA33298B1 (es) |
| MX (1) | MX2011011119A (es) |
| MY (1) | MY155288A (es) |
| NZ (1) | NZ596431A (es) |
| PL (1) | PL2421534T3 (es) |
| PT (1) | PT2421534E (es) |
| RS (1) | RS53539B1 (es) |
| SG (1) | SG175124A1 (es) |
| SI (1) | SI2421534T1 (es) |
| SM (1) | SMT201400159B (es) |
| TN (1) | TN2011000504A1 (es) |
| TW (1) | TWI461224B (es) |
| UA (1) | UA106985C2 (es) |
| WO (1) | WO2010121621A1 (es) |
| ZA (1) | ZA201107731B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2421534T1 (sl) | 2009-04-24 | 2014-11-28 | H. Lundbeck A/S | Tekoče formulacije soli 1-(2-(2,4-dimetilfenilsulfanil) fenil) piperazina |
| BR112015006075B1 (pt) * | 2012-09-19 | 2022-10-04 | Sandoz Ag | Composto cristalino, composição farmacêutica, uso do composto cristalino, hidrato cristalino do bromidrato de vortioxetina, método para a preparação do hidrato cristalino de bromidrato de vortioxetina, método para a preparação do composto cristalino e uso do hidrato cristalino de bromidrato de vortioxetina |
| EP3016937B1 (en) | 2013-07-01 | 2017-08-30 | LEK Pharmaceuticals d.d. | 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form |
| EP3099669A1 (en) | 2014-01-31 | 2016-12-07 | Egis Gyógyszergyár Zrt. | Process for the preparation of vortioxetine salts |
| CN104146953A (zh) * | 2014-07-24 | 2014-11-19 | 李雪梅 | 一种氢溴酸沃替西汀注射液 |
| CN104119299B (zh) * | 2014-08-13 | 2016-08-17 | 北京蓝贝望生物医药科技股份有限公司 | 沃赛汀或沃替西汀的氢溴酸盐 |
| CN104119298B (zh) * | 2014-08-13 | 2016-08-24 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
| GB201419261D0 (en) * | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
| WO2016125190A2 (en) | 2015-02-04 | 2016-08-11 | Mylan Laboratories Limited | Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof |
| JO3456B1 (ar) | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
| JP6987064B2 (ja) | 2016-02-08 | 2021-12-22 | ハー・ルンドベック・アクチエゼルスカベット | １−［２−（２，４−ジメチル−フェニルスルファニル）−フェニル］ピペラジンの合成 |
| TW201806599A (zh) | 2016-07-01 | 2018-03-01 | Ｈ 朗德貝克公司 | 用於快速開始抗抑鬱作用之給藥方案 |
| CN106518807A (zh) * | 2016-09-17 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 乳酸沃替西汀晶型的制备方法 |
| US10519121B2 (en) | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
| CN107011289A (zh) * | 2017-03-10 | 2017-08-04 | 万全万特制药（厦门）有限公司 | 沃替西汀β晶型的制备方法 |
| GB2564887A (en) * | 2017-07-26 | 2019-01-30 | Azad Pharmaceutical Ingredients Ag | New route of synthesis to vortioxetine salts |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| WO2021198778A1 (en) | 2020-04-03 | 2021-10-07 | H. Lundbeck A/S | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting |
| EP4681702A1 (en) * | 2024-07-16 | 2026-01-21 | PharmaPath S.A. | Oral solution comprising vortioxetine hydrobromide |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| DK1626720T3 (da) | 2003-04-04 | 2008-12-01 | Lundbeck & Co As H | 4-(2-Phenylsulfanyl-phenyl)-piperidinderivater som serotonin-genoptagelseshæmmer |
| CA2656057C (en) * | 2006-06-16 | 2012-10-02 | H. Lundbeck A/S | Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
| ATE540941T1 (de) * | 2006-06-16 | 2012-01-15 | Lundbeck & Co As H | 1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperaz n als verbindung mit kombinierter serotoninwiederaufnahme-, 5-ht3- und 5-ht1a- aktivität zur behandlung kognitiver störungen |
| TWI405588B (zh) * | 2007-03-20 | 2013-08-21 | Lundbeck & Co As H | ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物 |
| TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| SI2421534T1 (sl) | 2009-04-24 | 2014-11-28 | H. Lundbeck A/S | Tekoče formulacije soli 1-(2-(2,4-dimetilfenilsulfanil) fenil) piperazina |
-
2010
- 2010-04-16 SI SI201030759T patent/SI2421534T1/sl unknown
- 2010-04-16 RS RSP20140505 patent/RS53539B1/sr unknown
- 2010-04-16 WO PCT/DK2010/050084 patent/WO2010121621A1/en not_active Ceased
- 2010-04-16 MA MA34385A patent/MA33298B1/fr unknown
- 2010-04-16 SG SG2011073384A patent/SG175124A1/en unknown
- 2010-04-16 UA UAA201113335A patent/UA106985C2/uk unknown
- 2010-04-16 EA EA201171287A patent/EA021122B1/ru not_active IP Right Cessation
- 2010-04-16 PT PT107141640T patent/PT2421534E/pt unknown
- 2010-04-16 NZ NZ596431A patent/NZ596431A/xx unknown
- 2010-04-16 AU AU2010238946A patent/AU2010238946B2/en active Active
- 2010-04-16 BR BRPI1015338A patent/BRPI1015338C1/pt active IP Right Grant
- 2010-04-16 TW TW099111946A patent/TWI461224B/zh active
- 2010-04-16 ES ES10714164.0T patent/ES2512719T3/es active Active
- 2010-04-16 KR KR1020117025009A patent/KR101779214B1/ko active Active
- 2010-04-16 JP JP2012506342A patent/JP5722879B2/ja active Active
- 2010-04-16 EP EP10714164.0A patent/EP2421534B1/en active Active
- 2010-04-16 MX MX2011011119A patent/MX2011011119A/es active IP Right Grant
- 2010-04-16 CN CN201510093852.4A patent/CN104693145A/zh active Pending
- 2010-04-16 GE GEAP201012423A patent/GEP20135938B/en unknown
- 2010-04-16 PL PL10714164T patent/PL2421534T3/pl unknown
- 2010-04-16 CN CN2010800171058A patent/CN102405048A/zh active Pending
- 2010-04-16 CA CA2759456A patent/CA2759456C/en active Active
- 2010-04-16 MY MYPI2011004813A patent/MY155288A/en unknown
- 2010-04-16 US US13/265,564 patent/US8940746B2/en active Active
- 2010-04-16 HR HRP20140880AT patent/HRP20140880T1/hr unknown
- 2010-04-16 DK DK10714164.0T patent/DK2421534T3/da active
- 2010-04-23 AR ARP100101364A patent/AR076400A1/es not_active Application Discontinuation
-
2011
- 2011-09-25 IL IL215362A patent/IL215362A0/en active IP Right Grant
- 2011-10-07 TN TNP2011000504A patent/TN2011000504A1/en unknown
- 2011-10-19 CR CR20110554A patent/CR20110554A/es unknown
- 2011-10-20 DO DO2011000319A patent/DOP2011000319A/es unknown
- 2011-10-21 ZA ZA2011/07731A patent/ZA201107731B/en unknown
- 2011-10-21 CL CL2011002631A patent/CL2011002631A1/es unknown
- 2011-10-24 CO CO11143307A patent/CO6450649A2/es active IP Right Grant
-
2012
- 2012-07-27 DO DO2012000211A patent/DOP2012000211A/es unknown
-
2014
- 2014-10-29 SM SM201400159T patent/SMT201400159B/xx unknown
- 2014-12-11 US US14/567,003 patent/US9475748B2/en active Active
-
2015
- 2015-07-29 HK HK15107256.7A patent/HK1206732A1/xx unknown
-
2016
- 2016-09-21 US US15/271,543 patent/US10034876B2/en active Active
-
2018
- 2018-06-27 US US16/020,799 patent/US10857149B2/en active Active
-
2021
- 2021-05-10 AR ARP210101276A patent/AR122051A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011011119A (es) | Formulaciones liquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil) fenil] piperazina. | |
| ZA201105992B (en) | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine | |
| ZA201201360B (en) | New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine | |
| MX2010008583A (es) | Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico. | |
| CY1118886T1 (el) | Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης | |
| ITMI20110647A1 (it) | Procedimento migliorato per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib. | |
| IN2012DN01223A (es) | ||
| CY1115793T1 (el) | Υγρα σκευασματα αλατων 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο)φαινυλο]πιπεραζινης | |
| UA41094U (en) | Derivatives of 4-(bromomethyl)-2-r-1,3-thiazol-3-ium bromides and 4-bromomethyl-2-r-1,3-thiazoles | |
| UA35653U (en) | 2-(4-aryliden-2,5-dioxyimidazolidine-1-yl)-n-arylazetamides having antileukemic activity | |
| HK1168850A1 (zh) | 4-(二甲基胺基)丁基2-(4-((2-胺基-4-甲基-6-(戊基胺基)嘧啶-5-基)甲基)苯基)乙酸酯的糖精盐，富马酸盐，(1-羟基-萘-2-甲酸)盐和苯甲酸盐 | |
| UA44692U (ru) | СОЛИ ПРОИЗВОДНЫХ 2-(5-(ФУРАН-2-ИЛ)-4-R-1,2,4-ТРИАЗОЛ-3-ИЛТИО)АЦЕТАТНЫХ КИСЛОТ, КОТОРЫЕ ПРОЯВЛЯЮТ ГИПО-β-ЛИПОПРОТЕИНЕМИЧЕСКУЮ АКТИВНОСТЬ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GD | Licence granted |